Bristol Myers Squibb recently closed at $48.79, rising 1.06%, easily outpacing the S&P 500’s 0.41% gain. Despite this, the ...

Bristol-Myers announces $11 billion cancer partnership with BioNTech. CEO Boerner dubs the team up the next new frontier in ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

Boeing shares surged Thursday after the company said it will resume delivering planes to China next month. Monitor these key ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

C3.ai AI witnessed a 12.3% rise in its share price during the after-hours trading session yesterday, following the release of ...

Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...